Healthtech venture capital spans digital health platforms, care delivery innovation, diagnostics, and AI-enabled clinical workflows. Our healthtech coverage tracks the funding rounds and fund strategies defining the next generation of healthcare technology.
Browse healthtech venture capital articles below.
New York-based Eckuity Capital announced the first close of Fund II on June 26, 2026, extending its commercial-stage life sciences growth strategy across North America and Europe.
Star51 Capital announced the first close of its medtech fund in June 2026, led by Abbott and Mayo Clinic — a strategic-anchored vehicle bridging innovation and acquisition.
New York-based Star51 Capital announced the first close of its inaugural medtech venture fund on June 11, 2026, anchored by Abbott and Mayo Clinic.
Anagram Therapeutics, Ona Therapeutics, IMU Biosciences, and Garner Health show biotech and healthtech capital in 2026 favoring validated science and AI-enabled care.
New York-based Dimension Capital filed SEC Form D in June 2026 seeking up to $750M for its third fund, following $350M Fund I and $500M Fund II.
UK biotech IMU Biosciences extended its oversubscribed Series A past $53M in June 2026 to map and decode the human immune system for drug discovery.
